Skip to main content

Rarecell's CTC/CTM Technology Chosen for Study into Prostate Cancer

NEW YORK (GenomeWeb News) – French biotechnology firm Rarecells today announced that Ipsen and Institut Gustave Roussy, has selected its ISET technology for a study into patients with prostate cancer.

The technology is for circulating tumor cell and circulating tumor microemboli isolation.

The goal of the study is to use ISET, which stands for Isolation by Size of Epithelial/Throphoblastic Tumor cells, for the molecular analysis and genetic characterization of circulating cancer cells, Rarecells said.

"CTCs captured as a liquid biopsy from blood are expected to provide increasingly important clinical information on therapy choice, effectiveness, and drug resistance," Françoise Farace, head of the Circulating Cells Laboratory at Institut Gustave Roussy, said in a statement. "ISET is a powerful tool for capturing high levels of CTCs and [exploiting] them as a predictive biomarker in the context of personalized anticancer treatments."

Terms of the deal were not disclosed.

Based in Paris, Rarecells was founded in 2009 to commercialize the ISET technology

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.